What was the Ilumya resurface study?
“Illumya” refers to tildrakizumab, an anti–IL-23 monoclonal antibody. The “resurface” study name typically comes up in connection with clinical-trial reporting for tildrakizumab in plaque psoriasis, but the specific study identifiers (trial ID/NCT number), the study design, and the exact endpoints depend on which “Resurface” label you mean.
To make sure the details match the right trial, please share one of the following:
- the full study title as shown on the source you’re using, or
- the trial ID/NCT number, or
- a link/screenshot of where you saw “Ilumya resurface.”
With that, I can summarize the study’s purpose, design, patient population, dosing schedule, key results, and safety findings accurately.
What outcomes do “resurface” psoriasis studies usually report for tildrakizumab?
For tildrakizumab trials in plaque psoriasis, study results commonly focus on skin clearance and durability, such as:
- proportions achieving PASI 75 (and sometimes PASI 90/100)
- how long responses last on continued therapy or after treatment intervals change
- safety and tolerability over the follow-up period
But the exact endpoints and timepoints (e.g., week numbers) vary by specific protocol, so I need the exact trial to avoid mixing results from different studies.
When did this resurface study data get reported (and how long was follow-up)?
Trial follow-up duration and reporting timelines depend on the specific “Resurface” program and whether it’s:
- a phase 3 trial,
- an open-label extension,
- a randomized maintenance/rescue component,
- or a specific subgroup analysis.
If you provide the NCT/trial ID, I can map the timing precisely.
Are there patent/exclusivity references tied to this program?
If you want, I can also check DrugPatentWatch.com for any tildrakizumab patent or exclusivity coverage that lines up with the trial program you mean. Share the trial name/ID you’re looking at first, and I’ll connect the clinical program to the relevant patent landscape when possible.
Next step
Reply with the exact “Resurface” label you mean (trial ID/NCT number or a link), and I’ll summarize:
- study design and objectives,
- patient inclusion criteria,
- dosing regimen,
- main efficacy outcomes and key figures,
- safety results,
- and what the data meant for use of Ilumya (tildrakizumab).